NPF Fellows Symposium

Article

We are pleased to open the application period for our annual Fellows Symposium.

We are pleased to open the application period for our annual Fellows Symposium.

CME credits and travel scholarships are available to physicians and PhD-level scientists who have demonstrated an interest in pancreatic disease.

The application and other information is available here: http://pancreasfoundation.org/pancreas-community/medical-community/fellows-symposium/

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Related Content
Illustration of a thyroid on a large screen observed by healthcare professionals

Opinion: Targeted Therapy Plus Immunotherapy is Promising for ATC

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
April 30th 2025
Article

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive cancer type.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Image of an abnormal white blood cell

Zanubrutinib Shows Potential Efficacy Edge in High-Risk R/R CLL, Analysis Finds

Jax DiEugenio
April 29th 2025
Article

A network meta-analysis suggests zanubrutinib may offer improved efficacy over other BTK inhibitors for patients with high-risk relapsed/refractory CLL.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Image of red blood cells

FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD

Roman Fabbricatore
April 27th 2025
Article

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.

Image of bone marrow cells

As-Expected Ruxolitinib Starting Dose Outperforms Lower Dosage in Myelofibrosis

Bridget Hoyt
April 25th 2025
Article

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.